Memphis, Tenn (PRWEB) May 02, 2014 -- Christie Medical Holdings, Inc., the inventor and global leader of direct projection vascular imaging systems, today unveiled VeinViewer® Vision2. VeinViewer is the first and only vein illumination medical device that uses harmless near-infrared light, DLP®, and other technologies to illuminate an exclusive real-time HD digital image of subcutaneous vasculature and blood patterns directly onto the skin surface.
"VeinViewer Vision2 is about listening to the hardest working person in the hospital, the floor nurse, and making the best even better," said Chris Schnee, general manager and vice president of sales and marketing for Christie. "They asked for head-to-toe imaging without needing to reposition the device. They asked for multiple color combinations to put them in control. We delivered. Their skills, our technology, better results when used together."
VeinViewer Vision2 Features
• Exclusive HD, digital full field (Df2) image using LED illumination
• New ASSESS™ Plus Imaging Suite comes standard with seven modes designed for ultimate image customization, including three new modes: TriColor which gives multiple color combinations for an image tailored to the patient's skin tone and the clinician's need, Image Capture collects static images of blood patterns for electronic medical record documentation and MaxBright providing the brightest image in the industry, necessary to adjust to varying lighting conditions
• MaxReach offers an 83 percent longer reach for easy head-to-toe assessment of a standard patient bed without having to reposition the device
• Christie Assure Program*, a revolutionary, industry-leading five-year customer commitment including utilization training, clinical education, warranty and upgrade path. Manufactured in the USA.
Attendees at the Medical World Americas conference in Houston, TX will be the first healthcare professionals to see VeinViewer Vision2 in person. Live demonstrations can be seen in the Christie booth, number 626, from April 28-30.
Proven Results
From the recent Infusion Nurses Society position on "Recommendations for Improving Safety Practices With Short Peripheral Catheters" vein visualization technology can "improve success rates, decrease unsuccessful insertion attempts, and improve patient satisfaction." Only Christie medical evidence was cited as the three supporting evidence papers in the panel's research regarding the recommendation.
VeinViewer has been shown to increase peripheral intravenous (PIV) first-stick success by up to 100 percent, reduce medically unnecessary PICC placements by greater than 30 percent and improve patient satisfaction by 100 percent. VeinViewer technology was developed with the aid of the engineering capabilities and resources of parent company Christie Digital Systems, a leading global visual technology firm.
To learn more about Christie product offerings: VeinViewer Vision2, VeinViewer VisionXTND and VeinViewer Flex, please visit http://www.veinviewer.com.
*Please see Christie Assure Program terms and conditions.
About Christie Medical Holdings, Inc.
Christie Medical Holdings Inc. is a global company based in Memphis, Tenn., that discovers, develops and commercializes medical technologies. The company's market-leading product, VeinViewer, manufactured in the U.S., is a mobile vascular imaging system that allows health care providers to clearly see accessible vasculature as a real time HD image, directly on the surface of the skin. Christie Medical Holdings Inc. is owned by Christie Digital Systems Inc., a global visual technologies company and a subsidiary of Ushio Inc., Japan. For more information on Christie Digital Systems or Christie Medical Holdings, visit http://www.christiemed.com.
Follow us on Twitter - @veinviewer.
Christie® is a trademark of Christie Digital Systems USA, Inc., registered in the United States of America and certain other countries.
DLP® is a registered trademark of Texas Instruments.
John Berkovich, Christie Digital Systems Canada Inc., http://www.christiedigital.com, +1 (519) 497-8772, [email protected]
Share this article